Quick Answer
Oncotelic Therapeutics, Inc. reported Operating Income Loss of -$3.58 million for the year ending 2024.
- Oncotelic Therapeutics, Inc. showed an increase of +46.2% in Operating Income Loss from 2023 to 2024.
- This data is from Oncotelic Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2009 to 2024 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2012: -$1.89 million | Q2 2012: -$2.28 million | Q3 2012: -$2.24 million | Q1 2013: -$1.88 million | Q2 2013: -$1.66 million | Q3 2013: -$2.65 million | Q1 2014: -$2.63 million | Q2 2014: -$3.92 million | Q3 2014: -$3.45 million | Q1 2015: -$2.78 million | Q2 2015: -$3.33 million | Q3 2015: -$3.60 million | Q1 2016: -$3.35 million | Q2 2016: -$3.67 million | Q3 2016: -$3.26 million | Q1 2017: -$3.97 million | Q2 2017: -$3.90 million | Q3 2017: -$3.54 million | Q1 2018: -$795.0 thousand | Q2 2018: -$153.3 thousand | Q3 2018: -$214.0 thousand | Q1 2019: -$976.1 thousand | Q2 2019: -$1.16 million | Q3 2019: -$930.7 thousand | Q1 2020: -$2.65 million | Q2 2020: $13.8 thousand | Q3 2020: -$1.62 million | Q1 2021: -$2.04 million | Q2 2021: -$3.76 million | Q3 2021: -$1.81 million | Q1 2022: -$4.34 million | Q2 2022: -$256.3 thousand | Q3 2022: -$595.4 thousand | Q1 2023: -$264.1 thousand | Q2 2023: -$6.32 million | Q3 2023: $14.5 thousand | Q1 2024: -$167.2 thousand | Q2 2024: -$96.6 thousand | Q3 2024: -$3.28 million | Q1 2025: -$101.1 thousand | Q2 2025: -$66.0 thousand | Q3 2025: -$491.0 thousand.
- Over the full 16 years of available data (2009 to 2024), Oncotelic Therapeutics, Inc.'s Operating Income Loss has grown by 88.5%.
- Historical annual values: Fiscal year 2024: -$3.58 million | Fiscal year 2023: -$6.65 million | Fiscal year 2022: -$9.72 million | Fiscal year 2021: -$9.13 million | Fiscal year 2020: -$7.58 million | Fiscal year 2019: -$4.31 million | Fiscal year 2018: -$712.7 thousand | Fiscal year 2017: -$13.84 million | Fiscal year 2016: -$13.76 million | Fiscal year 2015: -$13.68 million | Fiscal year 2014: -$12.65 million | Fiscal year 2013: -$8.28 million | Fiscal year 2012: -$8.07 million | Fiscal year 2011: -$11.89 million | Fiscal year 2010: -$18.51 million | Fiscal year 2009: -$31.16 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: